Session

Oncogenes, tumour suppressor genes and molecular markers in renal cell carcinoma

Poster Session 74

  • Location:
    Room Berlin, North Hall (Level 1)
  • Chairs:
     A. Bex, Amsterdam (NL)
     K. Junker, Homburg (DE)
     M. Uemura, Toyonaka Osaka (JP)
  • Aims and objectives of this session

    To discuss the molecular biology of renal tumors

  • Poster viewing of 20 minutes. Presentations will take place on stage. Standard presentations are 2 minutes in length, followed by 2 minutes for discussion.
976
PD-L1 expression in Xp11.2 translocation renal cell carcinoma: Indicator of tumor aggressiveness

By: Qu Y-Y., Chang K., Dai B., Zhu Y., Zhang H-L., Ye D-W.

Institutes: Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China

977
Risk assessment for ccRCC patients based on alterations in specific chromosomal regions

By: Grimm J.1, Janssen M.1, Wagenpfeil S.2, Hartmann A.3, Stöhr C.3, Kunath F.4, Stöckle M.1, Junker K.1

Institutes: 1Saarland University Medical Center, Dept. of Urology and Pediatric Urology, Homburg/Saar, Germany, 2Saarland University Medical Center, Institute of Medical Biometry, Epidemiology and Medical Informatics, Homburg/Saar, Germany, 3University Hospital Erlangen, Institute of Pathology, Homburg/Saar, Germany, 4University Hospital Erlangen, Dept. of Urology, Homburg/Saar, Germany

978
Overexpression of miR-27a-3p is an independent prognostic factor for recurrence in clear cell renal cell carcinoma

By: Uemura M., Nakata W., Kawashima A., Ujike T., Nagahara A., Fujita K., Nonomura N.

Institutes: Osaka University Graduate School of Medicine, Dept. of Urology, Suita, Osaka, Japan

979
Validation and target identification of metastasis-associated miRNAs as prognostic markers in clear cell renal cell cancer

By: Heinzelmann J.1, Hoelters S.1, Arndt M.1, Pleyers R.1, Fecher-Trost C.2, Schalkowsky P.2, Janssen M.1, Pryalukhin A.3, Stöckle M.1, Junker K.1

Institutes: 1Saarland University, Dept. of Urology and Pediatric Urology, Homburg, Germany, 2University of The Saarland, Experimental and Clinical Pharmacology and Toxicology, Homburg, Germany, 3University Hospital of Saarland, Institute of Pathology, Homburg, Germany

980
Long noncoding RNA BX357664 regulates cell proliferation and epithelial-to-mesenchymal transition via inhibiting TGF-beta 1/p38/HSP27 signaling in renal cell carcinoma

By: Zengjun W., Liu Y., Qian J., Li X., Chen W., Xu A., Zhao K., Hua Y., Huang Z., Zhang J., Liang C., Su S., V P., Shao P., Li J., Qin C.

Institutes: The First Affiliated Hospital of Nanjing Medical University, Dept. of Urology, Nanjing, China

982
Functional variants in the low-density lipoprotein receptor gene are associated with clear cell renal cell carcinoma susceptibility

By: Zhang G-M.1, Wang M-Y.2, Zhu Y.3, Gu C-Y.3, Wan F-N.3, Wei Q-Y.2, Ye D-W.3

Institutes: 1The Affiliated Hospital of Qingdao University, Dept. of Urology, Qingdao, China, 2Fudan University Shanghai Cancer Center, Cancer Institute, Shanghai, China, 3Fudan University Shanghai Cancer Center, Dept. of Urology, Shanghai, China

983
Tumor suppressor versus oncogenic role of the new N-hydrolase DNPH1 in kidney and prostate cancers

By: Danilin S.1, Amiable C.2, Coquard C.1, Kaminski P-A.2, Paoletti J.2, Rothhut S.1, Hamaidi I.3, Lindner V4, Lang H.5, Pochet S.2, Massfelder T.1

Institutes: 1Inserm U1113, Team 3, Dept. of Cellular Signalisation and Communication In Kidney and Prostate Cancers, Strasbourg, France, 2Pasteur Institute, Biocatalyse and Chemistry Unit, Paris, France, 3Inserm U1113, Team 3, Cellular Signalisation and Communication In Kidney and Prostate Cancers, Strasbourg, France, 4Strasbourg University Hospital, Dept. of Pathology, Strasbourg, France, 5Strasbourg University Hospital, Dept. of Urology, Strasbourg, France

984
Epigenetic inactivation of HOXA11 as a novel functional tumor suppressor for renal cell carcinoma

By: Wang L., Cui Y., Sheng J.D., Yang Y., Kuang G.Y., Fan Y., Jin J., Zhang Q.

Institutes: Peking University First Hospital, Dept. of Urology, Beijing, China

985
Systematic expression analysis of the mitochondrial complex III subunits identifies UQCRC1 as biomarker in clear cell renal cell carcinoma

By: Ellinger J.1, Gromes A.1, Poss M.1, Brüggemann M.1, Schmdit D.1, Ellinger N.2, Tolkach Y.3, Dietrich D.3, Kristiansen G.3, Müller S.C.1

Institutes: 1Universitätsklinikum Bonn, Dept. of Urology, Bonn, Germany, 2Universitätsklinikum Bonn, Dept. of Anesthesia and Intensive Care, Bonn, Germany, 3Universitätsklinikum Bonn, Dept. of Pathology, Bonn, Germany

986
LOXL2 status correlates with tumor stage and regulates integrin levels to promote tumor progression in ccRCC

By: Uemura M.1, Hase H.2, Kawashima A.1, Ujike T.1, Nagahara A.1, Fujita K.1, Tsujikawa K.2, Nonomura N.1

Institutes: 1Osaka University Graduate School of Medicine, Dept. of Urology, Suita, Osaka, Japan, 2Osaka University Graduate School of Pharmaceutical Sciences, Laboratory of Molecular and Cellular Physiology, Suita, Osaka, Japan

987
Validation of BRCA1 associated protein-1 (BAP-1) as an adverse prognostic factor and investigations into the impact of BAP1 loss on the vascular endothelial growth factor (VEGF) pathway in clear cell renal cell carcinoma (ccRCC)

By: Skibbe M.2, Guenther K.2, Kapur P.3, Huang J.4, Belldegrun A.5, Burchardt M.1, Zimmermann U.1, Gu Y-F.6, Wolff N.6, Brugarolas J.6, Lillig C.2, Pantuck A.5, Kroeger N.1

Institutes: 1Ernst-Moritz-Arndt University Greifswald, Klinik und Poliklinik für Urologie, Greifswald, Germany, 2Ernst-Moritz-Arndt University Greifswald, Institute of Medical Biochemistry and Molecular Medicine, Greifswald, Germany, 3University of Texas Southwestern Medical Center, Dept. of Pathology, Dallas, United States of America, 4David Geffen School of Medicine, University of California-Los Angeles, Dept. of Pathology and Laboratory Medicine, Los Angeles, United States of America, 5David Geffen School of Medicine At The University of California Los Angeles, The Institute of Urologic Oncology, Department of Urology, Los Angeles, United States of America, 6University of Texas Southwestern Medical Center, Dept. of Internal Medicine, Dallas, United States of America

988
Targeting Lim1 oncogene has a therapeutic potential in advanced human renal cell carcinoma

By: Hamaidi I.1, Danilin S.2, Dormoy V.3, Rothhut S.1, Coquard C.1, Barthelmebs M.1, Béraud C.6, Lindner V.4, Lang H.5, Massfelder T.1

Institutes: 1Inserm U1113 Team 3, Dept. of Urology, Strasbourg, France, 2FIRALIS, Dept. of Urology, Hunningue, France, 3Inserm UMRS 903, Dept. of Urology, Reims, France, 4HUS, Hôpital De Hautepierre, Dept. of Pathology, Strasbourg, France, 5HUS, Nouvel Hôpital Civil, Dept. of Urology, Strasbourg, France, 6Urolead, Dept. of Urology, Strasbourg, France

989
Receptor activator of NFκB (RANK)-mediated induction of metastatic spread and association with poor prognosis in renal cell carcinoma

By: Steven A.1, Kroeger N.2, Leisz S.1, Fussek S.2, Nowroozizadeh B.3, Huang J.3, Brandstetter D.4, Dougall B.4, Burchardt M.2, Belldegrun A.5, Seliger B.6, Pantuck A.5

Institutes: 1Martin Luther University Halle/wittenberg, Medical Immunology At, Halle, Germany, 2Ernst-Moritz-Arndt University, Dept. of Urology, Greifswald, Germany, 3David Geffen School of Medicine At The University of California, Dept. of Pathology and Laboratory Medicine, Los Angeles, United States of America, 4Amgen Inc., Dept. of Hematology and Oncology Research, Seattle, United States of America, 5David Geffen School of Medicine At The University of California, Los Angeles, Institute of Urologic Oncology, Dept. of Urology, Los Angeles, United States of America, 6Martin Luther University Halle/wittenberg, Medical Immunology At, Halle, Unknown